Overview
On 10 June 2014, orphan designation (EU/03/14/1275) was granted by the European Commission to Gene Signal SAS, France, for aganirsen for the treatment of central retinal vein occlusion.
Key facts
Active substance |
Aganirsen
|
Intended use |
Treatment of central retinal vein occlusion
|
Orphan designation status |
Positive
|
EU designation number |
EU/03/14/1275
|
Date of designation |
10/06/2014
|
Sponsor |
Gene Signal SAS
4, rue Pierre Fontaine 91000 Evry France Tel. +33 155 6012 55 Fax +33 155 6012 56 E-mail: marconi@voisinconsulting.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: